Oncolytics Closes Offering of 8M Shares at $4/Share for Gross Proceeds of $32M

Oncolytics Biotech Inc.

announced today that it has closed its previously announced underwritten public offering of 8.0 million common shares, at a public offering price of US$4.00 per common share.  The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Oncolytics, were approximately US$32.0 million.